Recent advances in drug delivery systems for glaucoma treatment

Glaucoma is a chronic eye disease and the second most leading cause of irreversible impaired vision in the world, which is primarily linked with high intraocular pressure (IOP). The treatment of glaucoma is currently challenging because of the innate mechanics of ocular barriers that limit the penetration of ophthalmic drugs. To tackle this, various carriers (inorganic-, polymeric-, hydrogel-, or contact lens ebased) with specialized physical and chemical properties have been intensively studied. These carrierdrug formulations have shown significant improvement in various aspects, such as ocular barriers penetration, bioavailability, sustained release of drug, tissue targeting, and lowering the IOP. The delivery systems can be administered through various routes (intravitreal or periocular injection or systemic route), enabling the drugs to reach the damaged sites and help to recover the damaged optical nerves, thus considered an effective treatment strategy for glaucoma. In this review, we thoroughly investigate the recent advances in ocular delivery formulations focusing on glaucoma, including nanocarrier types, delivery route, and the efficacy in vitro and in vivo, clinical availability, and future outlook. (c) 2022 Elsevier Ltd. All rights reserved.

Automated summary

Glaucoma, a chronic eye disease associated with high intraocular pressure, poses challenges in drug treatment due to ocular barriers. Various carrier-drug formulations have shown improvements in ocular penetration, drug release, and lowering intraocular pressure. These delivery systems can be administered through different routes to target damaged sites, providing an effective treatment strategy for glaucoma.